LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.


Journal

Blood
ISSN: 1528-0020
Titre abrégé: Blood
Pays: United States
ID NLM: 7603509

Informations de publication

Date de publication:
03 10 2019
Historique:
received: 10 02 2019
accepted: 01 07 2019
pubmed: 2 8 2019
medline: 1 2 2020
entrez: 2 8 2019
Statut: ppublish

Résumé

Hematopoietic transcription factor LIM domain only 2 (LMO2), a member of the TAL1 transcriptional complex, plays an essential role during early hematopoiesis and is frequently activated in T-cell acute lymphoblastic leukemia (T-ALL) patients. Here, we demonstrate that LMO2 is activated by deacetylation on lysine 74 and 78 via the nicotinamide phosphoribosyltransferase (NAMPT)/sirtuin 2 (SIRT2) pathway. LMO2 deacetylation enables LMO2 to interact with LIM domain binding 1 and activate the TAL1 complex. NAMPT/SIRT2-mediated activation of LMO2 by deacetylation appears to be important for hematopoietic differentiation of induced pluripotent stem cells and blood formation in zebrafish embryos. In T-ALL, deacetylated LMO2 induces expression of TAL1 complex target genes

Identifiants

pubmed: 31366618
pii: S0006-4971(20)70774-3
doi: 10.1182/blood.2019000095
pmc: PMC6888148
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
LIM Domain Proteins 0
LMO2 protein, human 0
Proto-Oncogene Proteins 0
Transcription Factors 0
Zebrafish Proteins 0
lmo2 protein, zebrafish 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1159-1175

Informations de copyright

© 2019 by The American Society of Hematology.

Références

Cell Stem Cell. 2008 Mar 6;2(3):241-51
pubmed: 18371449
Science. 2010 Feb 12;327(5967):879-83
pubmed: 20093438
J Clin Oncol. 2011 Feb 10;29(5):475-86
pubmed: 21220609
Ann Hematol. 2017 Mar;96(3):345-353
pubmed: 27966038
Blood. 2017 Apr 13;129(15):2051-2060
pubmed: 28179281
Cell Signal. 2017 Oct;38:10-25
pubmed: 28645565
Cell. 1994 Jul 15;78(1):45-57
pubmed: 8033210
Cancer Chemother Pharmacol. 2010 May;65(6):1165-72
pubmed: 19789873
Nat Commun. 2015 Aug 26;6:8146
pubmed: 26306682
J Exp Med. 2005 Jun 6;201(11):1715-23
pubmed: 15928199
Clin Cancer Res. 2010 Dec 1;16(23):5618-23
pubmed: 20861166
Curr Opin Pharmacol. 2004 Feb;4(1):12-7
pubmed: 15018833
Proc Natl Acad Sci U S A. 1991 May 15;88(10):4367-71
pubmed: 2034676
Oncogene. 2014 Jan 23;33(4):403-10
pubmed: 23435431
Blood. 2007 Jul 15;110(2):743-51
pubmed: 17405906
J Biol Chem. 2012 Dec 14;287(51):42419-27
pubmed: 23086947
Oncogene. 1992 Dec;7(12):2389-97
pubmed: 1461647
Nat Methods. 2006 Dec;3(12):995-1000
pubmed: 17072308
J Exp Med. 2010 Sep 27;207(10):2141-56
pubmed: 20855495
EMBO J. 2018 Jul 13;37(14):
pubmed: 29880602
Am J Respir Crit Care Med. 2014 Jan 15;189(2):167-82
pubmed: 24279725
Nat Med. 2006 Oct;12(10):1191-7
pubmed: 17063141
Cell Rep. 2013 Jul 11;4(1):135-47
pubmed: 23831025
PLoS One. 2009 Nov 19;4(11):e7897
pubmed: 19936064
PLoS Comput Biol. 2014 Jul 24;10(7):e1003731
pubmed: 25058159
Chem Biol. 2013 Nov 21;20(11):1352-63
pubmed: 24183972
J Biol Chem. 2004 Dec 3;279(49):50754-63
pubmed: 15381699
Exp Hematol. 2004 Jan;32(1):11-24
pubmed: 14725896
Protein Pept Lett. 2009;16(8):977-83
pubmed: 19689425
Blood. 2017 Jun 15;129(24):3221-3226
pubmed: 28270453
Biochem Biophys Res Commun. 2012 Apr 20;420(4):714-20
pubmed: 22430142
Semin Hematol. 2003 Oct;40(4):274-80
pubmed: 14582078
Leuk Lymphoma. 2011 Jul;52(7):1348-59
pubmed: 21425961
Open Biol. 2015 Jun;5(6):150062
pubmed: 26108219
J Exp Med. 2018 Jan 2;215(1):51-62
pubmed: 29191913
Haematologica. 2015 Jun;100(6):e233-6
pubmed: 25682596
J Clin Invest. 2012 Oct;122(10):3398-406
pubmed: 23023710
Genome Res. 2017 Feb;27(2):185-195
pubmed: 27903646
Comput Biol Med. 2012 Apr;42(4):438-45
pubmed: 22270228
Exp Hematol. 2017 Jan;45:17-26
pubmed: 27833035
Hum Mol Genet. 2014 Mar 15;23(6):1644-55
pubmed: 24203696
Blood. 2009 Jun 4;113(23):5783-92
pubmed: 19171877
Biochem Biophys Res Commun. 2009 Sep 4;386(4):729-33
pubmed: 19559674
Blood. 2009 Apr 2;113(14):3276-86
pubmed: 19196867
Haematologica. 2014 Jan;99(1):19-27
pubmed: 23975175
Cancer Res. 2003 Nov 1;63(21):7436-42
pubmed: 14612543
Cell. 2008 Feb 22;132(4):631-44
pubmed: 18295580
Mol Cell Biol. 2004 Feb;24(4):1439-52
pubmed: 14749362
J Clin Invest. 2008 Sep;118(9):3143-50
pubmed: 18688286
Bioinformatics. 2005 Sep 15;21(18):3587-95
pubmed: 15994189
Blood. 2002 Nov 15;100(10):3749-56
pubmed: 12411322
Exp Hematol. 2016 Sep;44(9):838-849.e9
pubmed: 27302866
Genes Dev. 2006 May 15;20(10):1256-61
pubmed: 16648462
EMBO J. 1997 Jun 2;16(11):3145-57
pubmed: 9214632
Int J Cancer. 2013 Feb 15;132(4):766-74
pubmed: 22815158
Dev Dyn. 1995 Jul;203(3):253-310
pubmed: 8589427
J Leukoc Biol. 2019 May;105(5):935-946
pubmed: 30698851
Blood. 2011 Jan 13;117(2):440-50
pubmed: 20966168
Blood. 2006 Nov 15;108(10):3520-9
pubmed: 16873670
Neoplasma. 2017;64(4):494-501
pubmed: 28485154
Invest New Drugs. 2008 Feb;26(1):45-51
pubmed: 17924057
Nat Immunol. 2000 Aug;1(2):138-44
pubmed: 11248806
Blood. 2011 Feb 17;117(7):2146-56
pubmed: 21076045
PLoS One. 2014 Jan 21;9(1):e85883
pubmed: 24465765
Nat Med. 2009 Feb;15(2):151-8
pubmed: 19182797
N Engl J Med. 2003 Jan 16;348(3):255-6
pubmed: 12529469
J Cell Sci. 2011 Mar 15;124(Pt 6):833-8
pubmed: 21378304
Ann N Y Acad Sci. 2016 Jul;1375(1):38-51
pubmed: 27447537
Int J Tryptophan Res. 2010;3:113-20
pubmed: 22084593
J Exp Clin Cancer Res. 2014 Dec 18;33:106
pubmed: 25519934
Mol Cell Biol. 2011 Mar;31(5):1022-9
pubmed: 21199917
Mol Cell Biol. 2006 Jan;26(1):28-38
pubmed: 16354677
Leuk Lymphoma. 2011 Feb;52(2):290-7
pubmed: 21261500
Ann N Y Acad Sci. 2005 Jun;1044:29-40
pubmed: 15958695
Haematologica. 2012 Apr;97(4):551-9
pubmed: 22207684
Cytometry A. 2009 Oct;75(10):833-9
pubmed: 19650109
Blood. 2007 Mar 15;109(6):2389-98
pubmed: 17090656
Biochem Biophys Res Commun. 2006 Dec 1;350(4):818-24
pubmed: 17045240
Cell Death Dis. 2018 Aug 28;9(9):846
pubmed: 30154400
Blood. 2014 Apr 3;123(14):2229-37
pubmed: 24523240
Int J Cancer. 2002 Jan 10;97(2):230-6
pubmed: 11774269
Science. 2003 Oct 17;302(5644):415-9
pubmed: 14564000
Front Immunol. 2018 Dec 18;9:2969
pubmed: 30619326
Cancer Cell. 2011 Apr 12;19(4):484-97
pubmed: 21481790
Pigment Cell Melanoma Res. 2013 Mar;26(2):205-17
pubmed: 23205854
Nat Commun. 2016 Nov 08;7:13331
pubmed: 27824051
Oncotarget. 2014 Feb 28;5(4):1038-51
pubmed: 24657910
PLoS One. 2011;6(7):e22261
pubmed: 21818303
Haematologica. 2013 May;98(5):e59-61
pubmed: 23403321
Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):261-273
pubmed: 29879430
Am J Hematol. 2013 Sep;88(9):784-9
pubmed: 23757320
PLoS One. 2014 Feb 20;9(2):e89575
pubmed: 24586884

Auteurs

Tatsuya Morishima (T)

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Germany.

Ann-Christin Krahl (AC)

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Germany.

Masoud Nasri (M)

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Germany.

Yun Xu (Y)

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Germany.

Narges Aghaallaei (N)

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Germany.

Betül Findik (B)

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Germany.

Maksim Klimiankou (M)

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Germany.

Malte Ritter (M)

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Germany.

Marcus D Hartmann (MD)

Department of Protein Evolution, Max Planck Institute for Developmental Biology, Tübingen, Germany.

Christian Johannes Gloeckner (CJ)

German Center for Neurodegenerative Diseases, Tübingen, Germany.
Center for Ophthalmology, Institute for Ophthalmic Research, University Hospital Tübingen, Tübingen, Germany.

Sylwia Stefanczyk (S)

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Germany.

Christian Lindner (C)

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Germany.

Benedikt Oswald (B)

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Germany.

Regine Bernhard (R)

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Germany.

Karin Hähnel (K)

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Germany.

Ursula Hermanutz-Klein (U)

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Germany.

Martin Ebinger (M)

University Children's Hospital Tübingen, Tübingen, Germany.

Rupert Handgretinger (R)

University Children's Hospital Tübingen, Tübingen, Germany.

Nicolas Casadei (N)

Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen, Tübingen, Germany.

Karl Welte (K)

University Children's Hospital Tübingen, Tübingen, Germany.

Maya Andre (M)

University Children's Hospital Tübingen, Tübingen, Germany.
Department of Pediatric Intensive Care, University of Basel Children's Hospital, Basel, Switzerland; and.

Patrick Müller (P)

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Germany.
Friedrich Miescher Laboratory of the Max Planck Society, Tübingen, Germany.

Baubak Bajoghli (B)

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Germany.

Julia Skokowa (J)

Department of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH